Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models.
We recently developed a method to generate myeloid cells with proliferation capacity from human iPS cells. iPS-ML (iPS-cell-derived myeloid/macrophage line), generated by introducing proliferation and anti-senescence factors into iPS-cell-derived myeloid cells, grew continuously in an M-CSF-dependen...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3691167?pdf=render |
| _version_ | 1818791938843738112 |
|---|---|
| author | Chihiro Koba Miwa Haruta Yusuke Matsunaga Keiko Matsumura Eriko Haga Yuko Sasaki Tokunori Ikeda Koutaro Takamatsu Yasuharu Nishimura Satoru Senju |
| author_facet | Chihiro Koba Miwa Haruta Yusuke Matsunaga Keiko Matsumura Eriko Haga Yuko Sasaki Tokunori Ikeda Koutaro Takamatsu Yasuharu Nishimura Satoru Senju |
| author_sort | Chihiro Koba |
| collection | DOAJ |
| description | We recently developed a method to generate myeloid cells with proliferation capacity from human iPS cells. iPS-ML (iPS-cell-derived myeloid/macrophage line), generated by introducing proliferation and anti-senescence factors into iPS-cell-derived myeloid cells, grew continuously in an M-CSF-dependent manner. A large number of cells exhibiting macrophage-like properties can be readily obtained by using this technology. In the current study, we evaluated the possible application of iPS-ML in anti-cancer therapy. We established a model of peritoneally disseminated gastric cancer by intraperitoneally injecting NUGC-4 human gastric cancer cells into SCID mice. When iPS-ML were injected intraperitoneally into the mice with pre-established peritoneal NUGC-4 tumors, iPS-ML massively accumulated and infiltrated into the tumor tissues. iPS-ML expressing IFN-β (iPS-ML/IFN-β) significantly inhibited the intra-peritoneal growth of NUGC-4 cancer. Furthermore, iPS-ML/IFN-β also inhibited the growth of human pancreatic cancer MIAPaCa-2 in a similar model. iPS-ML are therefore a promising treatment agent for peritoneally disseminated cancers, for which no standard treatment is currently available. |
| first_indexed | 2024-12-18T15:19:18Z |
| format | Article |
| id | doaj.art-712899d05ff34b888f8187e939699949 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-18T15:19:18Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-712899d05ff34b888f8187e9396999492022-12-21T21:03:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0186e6756710.1371/journal.pone.0067567Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models.Chihiro KobaMiwa HarutaYusuke MatsunagaKeiko MatsumuraEriko HagaYuko SasakiTokunori IkedaKoutaro TakamatsuYasuharu NishimuraSatoru SenjuWe recently developed a method to generate myeloid cells with proliferation capacity from human iPS cells. iPS-ML (iPS-cell-derived myeloid/macrophage line), generated by introducing proliferation and anti-senescence factors into iPS-cell-derived myeloid cells, grew continuously in an M-CSF-dependent manner. A large number of cells exhibiting macrophage-like properties can be readily obtained by using this technology. In the current study, we evaluated the possible application of iPS-ML in anti-cancer therapy. We established a model of peritoneally disseminated gastric cancer by intraperitoneally injecting NUGC-4 human gastric cancer cells into SCID mice. When iPS-ML were injected intraperitoneally into the mice with pre-established peritoneal NUGC-4 tumors, iPS-ML massively accumulated and infiltrated into the tumor tissues. iPS-ML expressing IFN-β (iPS-ML/IFN-β) significantly inhibited the intra-peritoneal growth of NUGC-4 cancer. Furthermore, iPS-ML/IFN-β also inhibited the growth of human pancreatic cancer MIAPaCa-2 in a similar model. iPS-ML are therefore a promising treatment agent for peritoneally disseminated cancers, for which no standard treatment is currently available.http://europepmc.org/articles/PMC3691167?pdf=render |
| spellingShingle | Chihiro Koba Miwa Haruta Yusuke Matsunaga Keiko Matsumura Eriko Haga Yuko Sasaki Tokunori Ikeda Koutaro Takamatsu Yasuharu Nishimura Satoru Senju Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models. PLoS ONE |
| title | Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models. |
| title_full | Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models. |
| title_fullStr | Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models. |
| title_full_unstemmed | Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models. |
| title_short | Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models. |
| title_sort | therapeutic effect of human ips cell derived myeloid cells expressing ifn β against peritoneally disseminated cancer in xenograft models |
| url | http://europepmc.org/articles/PMC3691167?pdf=render |
| work_keys_str_mv | AT chihirokoba therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels AT miwaharuta therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels AT yusukematsunaga therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels AT keikomatsumura therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels AT erikohaga therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels AT yukosasaki therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels AT tokunoriikeda therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels AT koutarotakamatsu therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels AT yasuharunishimura therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels AT satorusenju therapeuticeffectofhumanipscellderivedmyeloidcellsexpressingifnbagainstperitoneallydisseminatedcancerinxenograftmodels |